Skip to content

Tirzepatide — Dual GIP/GLP-1 Receptor Agonist

Quick Facts

Development DesignationLY3298176
Peptide ClassDual GIP/GLP-1 Receptor Agonist (first-in-class)
Molecular TargetsGIP Receptor (GIPR) and GLP-1 Receptor (GLP-1R)
Amino Acid Length39 amino acids (modified GIP backbone with 14 amino acid substitutions)
Half-LifeApproximately 5 days (once-weekly dosing)
DeveloperEli Lilly and Company
DosingOnce weekly subcutaneous (2.5 mg initiation; 5, 10, 15 mg maintenance)
Key Structural FeatureC20 fatty diacyl chain at Lys20 enabling albumin binding; based on native GIP sequence with modifications for balanced GIPR/GLP-1R activity

Executive Summary

Tirzepatide (LY3298176) is a synthetic 39-amino acid peptide engineered as a first-in-class dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Developed by Eli Lilly and Company, tirzepatide represents a paradigm shift in incretin-based pharmacology: rather than targeting GLP-1R alone, it simultaneously activates two complementary incretin pathways, producing metabolic effects exceeding those achievable through selective GLP-1 receptor agonism.

The SURPASS clinical program established tirzepatide's superiority over selective GLP-1 receptor agonists for glycemic control in type 2 diabetes. SURPASS-2 demonstrated that all tirzepatide doses (5, 10, 15 mg) produced greater HbA1c reductions than semaglutide 1.0 mg, with the highest dose achieving a mean reduction of 2.37%. The SURMOUNT program established tirzepatide as the most effective obesity pharmacotherapy at the time of its approval, with mean body weight reductions of up to 22.5% at the 15 mg dose in SURMOUNT-1 — approaching bariatric surgery benchmarks and more than doubling the placebo-subtracted weight loss of earlier-generation weight management medications.

Tirzepatide was the first dual incretin agonist to receive FDA approval, initially for type 2 diabetes (2022, brand name Mounjaro) and subsequently for chronic weight management (2023, brand name Zepbound). For researchers, tirzepatide represents the clinical validation of multi-receptor incretin pharmacology and serves as the foundation for the next generation of metabolic peptide therapeutics, including triple agonists such as retatrutide. Key research takeaways include the importance of balanced GIPR/GLP-1R activity ratios, the potential for GIPR agonism to enhance metabolic efficacy while modulating GI tolerability, and the demonstration that dual incretin agonism can achieve weight loss approaching surgical benchmarks.

Background

The development of tirzepatide was grounded in a fundamental reappraisal of the role of glucose-dependent insulinotropic polypeptide (GIP) in metabolic physiology. GIP was the first incretin hormone identified — discovered in the 1970s and initially named "gastric inhibitory polypeptide" for its effects on gastric acid secretion. Its insulinotropic properties were recognized shortly thereafter, establishing it alongside GLP-1 as one of the two primary incretin hormones responsible for the augmented insulin response to oral versus intravenous glucose (the "incretin effect").

Despite its insulinotropic potency, GIP was historically viewed as an unattractive therapeutic target in type 2 diabetes. Observations from the 1990s and early 2000s demonstrated that the insulinotropic response to exogenous GIP infusion was markedly attenuated in patients with type 2 diabetes — a phenomenon termed "GIP resistance." This finding, combined with the successful development of GLP-1 receptor agonists (exenatide, liraglutide), led the field to focus almost exclusively on GLP-1R as the therapeutic incretin target for nearly two decades.

However, emerging evidence from the 2010s suggested a more nuanced picture. Pharmacological levels of GIP receptor activation — substantially exceeding physiological postprandial GIP concentrations — could overcome the apparent resistance and stimulate insulin secretion even in diabetic states. Furthermore, GIPR activation was found to exert distinct metabolic effects not shared by GLP-1R agonism: improved adipose tissue lipid handling, enhanced insulin sensitivity, positive effects on bone metabolism, and potential interactions with central nervous system feeding circuits. Most provocatively, preclinical studies suggested that GIPR activation might attenuate the nausea and emetic responses associated with GLP-1R activation — a hypothesis that, if validated in humans, could address the dose-limiting gastrointestinal adverse effects of selective GLP-1R agonists.

The Eli Lilly research team, building on the pioneering conceptual work of Tschöp, DiMarchi, and colleagues on multi-receptor peptide pharmacology, undertook a systematic medicinal chemistry campaign to design a peptide with balanced and sustained agonist activity at both GIPR and GLP-1R. The foundational insight was to build the molecule on a modified GIP backbone rather than a GLP-1 backbone, as GIP's native sequence already encoded strong GIPR activity; GLP-1R activity was then engineered through iterative amino acid substitution guided by structure-activity relationship studies. The result, LY3298176 (tirzepatide), incorporated 14 amino acid substitutions relative to native GIP and a C20 fatty diacid moiety at Lys20 for albumin binding, achieving a half-life of approximately 5 days with balanced dual-receptor pharmacology.

Core Science

Mechanism of Action

Tirzepatide simultaneously activates GIPR and GLP-1R — both class B (secretin family) G protein-coupled receptors — with distinct and complementary downstream effects:

GIP Receptor Activation: GIPR is expressed on pancreatic beta cells, adipocytes, osteoblasts, certain CNS nuclei, and the gastrointestinal tract. In beta cells, GIPR activation stimulates glucose-dependent insulin secretion through the Gαs–cAMP–PKA–Epac2 cascade, analogous to GLP-1R signaling. Beyond insulin secretion, GIPR activation in adipose tissue promotes postprandial lipid uptake and storage, enhances insulin-stimulated glucose disposal, and may improve adipose tissue insulin sensitivity — an effect particularly relevant in states of insulin resistance where adipose tissue dysfunction contributes to systemic metabolic dysregulation. In bone, GIPR signaling suppresses bone resorption and may promote bone formation. In the CNS, GIPR-expressing neurons in hypothalamic and brainstem regions involved in feeding regulation may contribute to appetite modulation, though the precise role of central GIPR signaling in feeding behavior remains less well-defined than for GLP-1R.

GLP-1 Receptor Activation: GLP-1R signaling potentiates glucose-dependent insulin secretion (beta cells), suppresses glucagon release (alpha cells, through somatostatin-dependent paracrine mechanisms), delays gastric emptying (vagal afferent signaling), and reduces appetite through central actions in hypothalamic (arcuate nucleus, paraventricular nucleus) and brainstem (area postrema, nucleus tractus solitarius) nuclei. These GLP-1R-mediated effects are well-characterized from extensive research on selective GLP-1R agonists including semaglutide.

Synergy and Emergent Properties: The combination of GIPR and GLP-1R activation produces several effects not achievable through either pathway alone:

  1. Enhanced insulin secretion: Dual agonism produces supra-additive insulinotropic effects compared to either receptor agonist alone at equivalent receptor occupancy, potentially through distinct intracellular signaling kinetics and cAMP compartmentalization.

  2. Improved insulin sensitivity: GIPR-mediated effects on adipose tissue lipid handling and glucose disposal — combined with GLP-1R-mediated weight loss — produce greater improvements in insulin sensitivity than GLP-1R agonism alone.

  3. Gastrointestinal tolerability modulation: Preclinical evidence and clinical observations suggest GIPR activation may reduce GLP-1R-mediated nausea and emesis. At equivalent levels of GLP-1R activation (assessed by gastric emptying delay and other pharmacodynamic biomarkers), tirzepatide produces less nausea than selective GLP-1R agonists — a potential advantage enabling higher effective doses and greater metabolic efficacy.

  4. Lipid metabolism: GIPR activation promotes coordinated postprandial lipid handling — enhanced adipose tissue lipid uptake, reduced circulating free fatty acids, and improved lipid storage capacity in subcutaneous (as opposed to visceral/ectopic) depots. Combined with GLP-1R-mediated weight loss, this produces favorable changes in lipid profiles including reduced triglycerides and improved HDL cholesterol.

Structure-Activity Relationships

Tirzepatide is a 39-amino acid peptide built on a modified GIP backbone. The native GIP sequence was selected as the template because it provides strong endogenous GIPR activity; systematic amino acid substitutions — 14 positions relative to native GIP — were then introduced to engineer balanced GLP-1R activity while preserving GIPR potency. Key structural features include:

  • C20 fatty diacid moiety at Lys20: The eicosanedioic acid chain, conjugated via a glutamic acid linker to Lys20, enables high-affinity non-covalent albumin binding, extending the half-life to approximately 5 days. The C20 chain length provides optimal albumin binding for once-weekly dosing — longer than liraglutide's C16 chain (once daily) and optimized for the pharmacokinetic requirements of sustained dual receptor activation.

  • Aib residues at multiple positions: Alpha-aminoisobutyric acid (Aib) substitutions confer DPP-4 resistance and stabilize alpha-helical secondary structure, enhancing receptor binding and metabolic stability.

  • C-terminal amidation: Protects against carboxypeptidase degradation and stabilizes the peptide's bioactive conformation.

The relative receptor potency ratio — GIPR agonism is preserved at near-native potency while GLP-1R activity is engineered to intermediate levels — was informed by preclinical data indicating that strong GIPR agonism relative to GLP-1R agonism optimizes both metabolic efficacy and gastrointestinal tolerability.

Pharmacological Properties

Following subcutaneous administration, tirzepatide reaches peak plasma concentrations at 24–72 hours, with steady-state achieved after approximately 4 weeks of once-weekly dosing. The extended absorption phase reflects slow release from the subcutaneous depot. The terminal elimination half-life of approximately 5 days (117 hours) supports once-weekly administration with stable therapeutic concentrations throughout the dosing interval. The peptide is eliminated through proteolytic degradation and renal clearance of metabolites.

The dose-escalation regimen — starting at 2.5 mg for 4 weeks, then escalating to 5 mg, with further increases to 10 mg and 15 mg at ≥4-week intervals guided by therapeutic response and tolerability — is designed to allow gradual adaptation to GI effects. The maximum approved maintenance dose is 15 mg once weekly.

Clinical Evidence

The clinical development of tirzepatide is anchored by two comprehensive phase 3 programs:

SURPASS (type 2 diabetes): SURPASS-1 through SURPASS-5 evaluated tirzepatide across the treatment continuum — as monotherapy, in combination with metformin, SGLT2 inhibitors, and basal insulin — in diverse patient populations. SURPASS-2, the head-to-head comparison with semaglutide 1.0 mg, demonstrated superiority of all tirzepatide doses for HbA1c reduction (mean reductions: 5 mg −2.09%, 10 mg −2.37%, 15 mg −2.37% vs semaglutide −1.86%). SURPASS-4 demonstrated cardiovascular safety and superiority over insulin glargine in patients with high cardiovascular risk. Across the program, 85–97% of participants achieved HbA1c <7.0%, and body weight reductions ranged from 7.0–12.4 kg depending on dose and background therapy.

SURMOUNT (obesity): SURMOUNT-1 (n=2,539) reported mean body weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) at 72 weeks versus 3.1% for placebo — with the 15 mg group achieving 22.5% mean weight reduction at the maximum effect time point. SURMOUNT-2 demonstrated efficacy in participants with obesity and type 2 diabetes. SURMOUNT-3 and SURMOUNT-4 established the role of intensive lifestyle intervention preceding pharmacotherapy and the durability of weight loss maintenance with continued treatment, respectively. SURMOUNT-5 is a head-to-head comparison with semaglutide 2.4 mg. The SURPASS-CVOT cardiovascular outcomes trial and the SYNERGY-NASH MASH program are ongoing.

Research Evidence

Finding Data Source
HbA1c reduction (SURPASS-2, 15 mg) −2.37% vs −1.86% semaglutide N Engl J Med. (2021)
Weight reduction (SURMOUNT-1, 15 mg, 72 wk) −20.9% vs −3.1% placebo N Engl J Med. (2022)
Weight reduction (SURMOUNT-1, 15 mg, max) −22.5% N Engl J Med. (2022)
≥20% weight loss (SURMOUNT-1, 15 mg) 57% of participants N Engl J Med. (2022)
HbA1c <7.0% achievement (SURPASS-2, 15 mg) 92% of participants N Engl J Med. (2021)
HbA1c reduction (SURPASS-4, 15 mg) −2.58% vs −1.44% glargine Lancet. (2021)
Waist circumference (SURMOUNT-1, 15 mg) −18.5 cm N Engl J Med. (2022)
Triglyceride reduction (SURMOUNT-1, 15 mg) −31.4% N Engl J Med. (2022)
Nausea (SURPASS-2, 15 mg) 22% (mild-moderate, transient) N Engl J Med. (2021)
Half-life (subcutaneous) ~117 hours (5 days) Lancet. (2021)
GIPR binding (cAMP, relative to native GIP) ~100% potency Nat Metab. (2018)
GLP-1R binding (cAMP, relative to native GLP-1) ~13% potency (balanced dual action) Nat Metab. (2018)

FAQ

Q: What makes tirzepatide different from selective GLP-1 receptor agonists like semaglutide?

A: Tirzepatide simultaneously activates both GIP and GLP-1 receptors, whereas selective GLP-1 receptor agonists such as semaglutide activate only GLP-1R. The addition of GIPR agonism provides complementary metabolic benefits — enhanced insulin sensitivity through adipose tissue effects, improved lipid metabolism, and potentially modulation of gastrointestinal tolerability — that are not achievable through GLP-1R agonism alone. In head-to-head trials, tirzepatide demonstrated superior efficacy for both glycemic control and weight reduction compared to semaglutide 1.0 mg (SURPASS-2), and the ongoing SURMOUNT-5 trial will provide direct comparison at the highest approved doses for weight management.

Q: What is tirzepatide's molecular structure?

A: Tirzepatide is a 39-amino acid peptide built on a modified human GIP backbone. It incorporates 14 amino acid substitutions relative to native GIP — including Aib residues at multiple positions for DPP-4 resistance — and a C20 fatty diacid (eicosanedioic acid) moiety conjugated via a glutamic acid linker to lysine at position 20 for albumin binding. The peptide is C-terminally amidated for stability. This design preserves near-native GIPR potency while engineering intermediate GLP-1R activity, achieving the balanced dual-receptor pharmacology that defines tirzepatide's mechanism.

Q: How does tirzepatide compare to semaglutide for glycemic control?

A: In the SURPASS-2 head-to-head trial, tirzepatide 5 mg, 10 mg, and 15 mg once weekly all demonstrated statistically significant and clinically meaningful superiority over semaglutide 1.0 mg once weekly for HbA1c reduction. Tirzepatide 15 mg achieved mean HbA1c reduction of 2.46% versus 1.93% for semaglutide (treatment policy estimand), and 92% of tirzepatide 15 mg participants achieved HbA1c <7.0% versus 81% for semaglutide. The magnitude of glycemic improvement with tirzepatide is among the largest reported for any glucose-lowering therapy not associated with hypoglycemia risk.

Q: What weight reductions have been observed with tirzepatide?

A: In SURMOUNT-1, the primary analysis at 72 weeks demonstrated mean body weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) compared to 3.1% with placebo. At the maximum efficacy time point, the 15 mg dose produced 22.5% mean weight reduction — the largest weight loss reported for any pharmacotherapy at the time. More than half of participants (57%) achieved ≥20% weight loss at the 15 mg dose. These results approach the weight loss typically reported after sleeve gastrectomy (25–30%), effectively bridging the gap between pharmacotherapy and bariatric surgery for the first time.

Q: Why include GIP agonism if GIP resistance was reported in diabetes?

A: The concept of "GIP resistance" described reduced insulinotropic response to physiological postprandial GIP concentrations in type 2 diabetes. However, pharmacological levels of GIP agonism — substantially exceeding physiological concentrations — overcome this apparent resistance and stimulate insulin secretion even in diabetic states. Furthermore, GIPR activation provides distinct metabolic benefits beyond insulin secretion — improved adipose tissue insulin sensitivity, enhanced postprandial lipid handling, potential bone effects, and possible modulation of GLP-1R-mediated gastrointestinal adverse events. Clinical data from the SURPASS and SURMOUNT programs strongly support that the dual GIPR/GLP-1R agonism approach produces superior metabolic outcomes compared to selective GLP-1R agonism.

Q: Does tirzepatide have cardiovascular benefits?

A: The SURPASS-4 trial, conducted in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, demonstrated a favorable cardiovascular safety profile with tirzepatide compared to insulin glargine, with no increase in MACE risk. The dedicated SURPASS-CVOT cardiovascular outcomes trial — a large-scale, event-driven trial comparing tirzepatide to dulaglutide — is ongoing and will provide definitive data on cardiovascular event reduction. Secondary analyses of SURPASS and SURMOUNT programs have demonstrated improvements in cardiovascular risk factors including blood pressure, lipid profiles, and inflammatory markers that would be expected to translate into cardiovascular benefit.

Q: What are the primary adverse events with tirzepatide?

A: Gastrointestinal adverse events — nausea (12–22%), diarrhea (12–19%), vomiting (5–12%), decreased appetite (5–11%), and constipation (6–11%) — are the most commonly reported, consistent with the GLP-1 receptor agonist class. Notably, the incidence and severity of gastrointestinal events with tirzepatide appear comparable to or lower than those reported for selective GLP-1R agonists at equivalent levels of glycemic and weight efficacy — a potential advantage attributed to GIPR-mediated modulation of GLP-1R-induced nausea. GI events are predominantly mild to moderate, occur primarily during dose escalation, and diminish substantially with continued treatment. The dose-escalation regimen (starting 2.5 mg, increasing at ≥4-week intervals) is designed to improve tolerability.

Q: Is tirzepatide being studied for MASH (formerly NASH)?

A: Yes. The SYNERGY-NASH program is evaluating tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). GIPR activation is hypothesized to influence hepatic lipid metabolism through improved adipose tissue insulin sensitivity (reducing portal free fatty acid flux to the liver) and potential direct effects on hepatocyte lipid handling. Combined with GLP-1R-mediated weight loss and metabolic improvement, tirzepatide's dual mechanism may offer advantages over selective GLP-1R agonists for MASH. The SYNERGY-NASH trials include liver biopsy endpoints — resolution of steatohepatitis without worsening of fibrosis, and improvement in fibrosis without worsening of steatohepatitis — the standard regulatory endpoints for MASH therapeutics.

Q: How does the dosing schedule work, and why is escalation necessary?

A: Tirzepatide is initiated at 2.5 mg once weekly for 4 weeks, then escalated to 5 mg weekly. Further dose increases to 10 mg and then 15 mg can be made at ≥4-week intervals based on tolerability and therapeutic goals. The stepwise dose escalation allows gradual adaptation of the gastrointestinal system to increasing GLP-1R activation — minimizing the severity and duration of nausea, vomiting, and other GI adverse events. In clinical trials, most GI events occurred during the initial dose-escalation period (first 8–20 weeks) and diminished substantially thereafter. Once a maintenance dose is achieved, the weekly injection schedule is maintained indefinitely.

Q: What are the limitations and future directions for tirzepatide research?

A: Key limitations and research directions include: (1) completion of the SURPASS-CVOT cardiovascular outcomes trial to definitively establish cardiovascular event reduction; (2) results from SYNERGY-NASH with histological endpoints for MASH; (3) long-term safety data beyond 2–3 years, particularly effects on bone metabolism (given GIP's role in bone), thyroid C-cell safety (based on rodent models), and pancreatitis risk; (4) better characterization of lean body mass loss alongside fat mass reduction — studies suggest 20–40% of weight lost may be lean mass, and strategies to preserve muscle during weight loss are clinically important; (5) investigation of weight regain patterns and metabolic adaptation after treatment discontinuation; (6) direct comparison with retatrutide (triple agonist) to establish the incremental benefit of adding glucagon receptor agonism; and (7) exploration of tirzepatide in pediatric obesity, prediabetes, heart failure with preserved ejection fraction (HFpEF), and obstructive sleep apnea.

References

  1. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
  3. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6
  4. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. doi:10.1016/S0140-6736(21)02188-7
  5. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021;398(10300):583-598. doi:10.1016/S0140-6736(21)01443-4
  6. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Nat Metab. 2018;1(4):439-449. doi:10.1038/s42255-018-0007-6
  7. Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-420. doi:10.1016/j.tem.2020.02.006
  8. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157. doi:10.1053/j.gastro.2007.03.054
  9. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837. doi:10.1016/j.cmet.2013.04.008
  10. Tschöp MH, DiMarchi RD. Single-molecule combinatorial therapeutics for treating obesity and diabetes. Diabetes. 2017;66(7):1766-1769. doi:10.2337/dbi16-0086
  11. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36. doi:10.1038/nm.3761
  12. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001
  13. Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP-1. Nat Rev Endocrinol. 2023;19:201-216. doi:10.1038/s41574-022-00783-3
  14. Gimeno RE, Briere DA, Seeley RJ. Leveraging the gut to treat metabolic disease. Cell Metab. 2020;31(4):679-698. doi:10.1016/j.cmet.2020.02.014
  15. El K, Campbell JE. The role of GIP in α-cells and glucagon secretion. Peptides. 2020;125:170213. doi:10.1016/j.peptides.2019.170213

About RPL Peptide: RPL Peptide is a supplier of high-purity research peptides with comprehensive analytical documentation including HPLC, LC-MS, and Certificates of Analysis (COA). For researchers requiring certified reference materials for laboratory investigations, visit rplpeptides.com or explore detailed molecular data at the RPL Peptide Data Center.

— Written by the RPL Scientific Editorial Team | Last updated August 2025

Related Articles: Semaglutide Research Profile | Retatrutide Research Profile | GLP-1/GIP Dual Agonist Research | Semaglutide vs Tirzepatide | RPL Peptide | Peptide Research Data